Rhodopsin targeted transcriptional silencing by DNA-binding

Thank you for submitting your work entitled "Gene-targeted transcriptional silencing by DNA-binding" for consideration by eLife. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor (Jeremy Nathans) and a Senior Editor.

The following individual involved in review of your submission has agreed to reveal their identity: Eric Pierce (peer reviewer).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The manuscript has been reviewed by three expert reviewers, and their assessments together with my own (Reviewing editor), form the basis of this letter.

All of the reviewers were impressed with the importance and novelty of your work, and we would like to see a revision that addresses the issues raised.

I am including the three reviews (lightly edited) at the end of this letter, as there are some specific and useful suggestions in them that will not be repeated in the summary here. Also, we think that this manuscript would be a better fit as a "Tools and Resources" paper rather than a regular research paper.

The main issues, which I have extracted from the reviews and the subsequent discussion between the reviewers and me, are:

1) Revisions to the text that focus the story on use of the ZF6-DB to suppress RHO expression. This could be accomplished by changing the title, and revising the Introduction and Discussion. We would favor moderating the claims about potential clinical use of this approach since the repression-replacement approach wasn't tested in a disease model.

2) There is a question of ZF6-DB specificity and efficiency. Please provide the porcine, human, and mouse RHO TSS sequences for comparison, since it appears that the ZF6-DB recognizing hRHO TSS was used in these models regardless of any differences between the sequences. Does ZF6-DB recognize the porcine and mouse sequence? As to clinical therapeutic potential, how do the pig and human repression efficiencies compare? Is the 35% repression of Rho expression sufficient for dominant disease? These are important questions that could be addressed by supplying the sequences and the related data.

3) It is unclear why cone arrestin increases in Arr3. This suggests that there may be off-target effects. Does ZF6-DB also bind to the Arr3 TSS region? ChIP data should be supplied to address off-target issues.

4) Figure 3 would benefit from the presentation of wild type mouse data. For example, eGFP, ZF6-KRAB, and ZF6-DB treatments of wild type mice to serve as a point of comparison and investigate the efficiency of ZF6-DB suppression of human and mouse rhodopsin respectively.

5) Regarding the repression-replacement experiment described in Figure 4, it is not clear why a different promoter (CMV) was used in the control ZF6-DB vector than that used for the ZF6-DB cassette (modified RHO promoter) in the in the experimental ZF6-DB – RHO expression vector.

6) The level of repression of the RHO gene achieved in the repression-replacement experiment described in Figure 4 is moderate. It is likely that greater than 35% suppression of a mutant RHO allele would be needed to have a therapeutic effect for patients affected by retinal degeneration due to gain-of-function mutations in RHO. While the data reported in Figure 1 suggest that repression of RHO expression in transduced photoreceptor cells is closer to 90%, it is unclear if suppressing RHO expression in 35% of photoreceptor cells would be therapeutic. Additional experiments to optimize the dose response and evaluate the potential of this approach for therapeutic use are needed to support the claim that a ZF6-DB based approach has the potential to be used clinically.

7) Clarity of presentation as indicated below by reviewers #2 and #3.

We look forward to receiving the revised version of your manuscript.

Reviewer #1:

Summary: Botta et al. report a method for gene-specific transcriptional silencing using an engineered DNA-binding domain, "ZF6-DB." AAV-mediated expression of ZF6-DB in photoreceptors resulted in blockade of Rho expression, leading to therapeutic effects in animal models with gain-of-function cis- Rho mutations, such as autosomal dominant retinitis pigmentosa.

Feedback:

Experiment 1-showed the 20 bp in ZF6-cis is required for Rho expression via eGFP reporter assay. ChIP showed ZF6-DB binds well to CRE. Put ZF6-DB into porcine retina using AAV and measured Rho transcripts, which were decreased. Finally, they compared ZF6-DB with eGFP expression levels

Criticism: n = 2 is a low number. They should supplement their claims with additional data points.

Experiment 2-Compared Rho transcription levels between ZF6-KRAB and ZF6-DB, found greater repression using ZF6-DB and less transcriptional perturbation.

Criticism: They claim that ZF6-KRAB and ZF6-DB bind to same genomic targets, but they didn't explain or otherwise address the possibility that the difference in the transcription perturbations may in fact be caused by off-targeting effects or the down-regulation of RHO expression. Should perform ChIP to confirm the two are binding to the same region (as well as Crx and Nrl). Figure 2C is confusing: comparing before and after ZF6-DB treatments, rather than different constructs would be more helpful.

Experiment 3-Compared the ERG a and b waves in the P347S RP murine model and saw much greater rescue in ZF6-DB compared with ZF6-KRAB or eGFP.

Criticism: they should further explore the reason that ZF6-DB has such a greater rescue than ZF6-KRAB despite their similar binding affinity (according to Figure 2—figure supplement 2). This is a surprising discrepancy that merits exploration and explanation. It would also be helpful for them to repeat this experiment in wild type animals to see if ZF6-DB also represses RHO expression and compare the percentage of repression in wild type and R347S alleles.

Experiment 4-Created construct with ZF6-DB and hRHO and found suppression of mutant mouse Rho and expression of the hRHO.

Criticism: unclear why they didn't consistently use the CMV promoter and opted for the truncated Rho promoter, despite similar repression levels of RHO. Any rescue beyond P30?

Reviewer #2:

This manuscript describes the use of a synthetic DNA binding protein to interfere with expression of the RHO gene. The experiments described build on prior work in which a hybrid protein consisting of a DNA binding domain coupled to a KRAB repressor domain was used to repress expression of the RHO gene. In this study, the activity of the DNA binding domain alone was evaluated.

It seems that the manuscript attempts to achieve two goals, and does not completely succeed for either. One focus is the potentially general idea that DNA binding proteins alone targeted to regulatory elements can be used to regulate expression of target genes. The data presented regarding the ZF6-DB for RHO support this idea, but without testing this hypothesis for other genes, the potential to use this approach more generally remains in question. The second focus is the idea that repression of RHO could be used therapeutically in patients with retinal degeneration caused by dominant, gain-of-function mutations in this gene. Since the ZF6-DB mediated repression of RHO expression isn't specific for the mutant allele, a repression-replacement strategy would be needed in patients. The tests of this approach described in the manuscript show some efficacy, but fall short of being convincing.

Specific comments are as follows:

1) Additional studies of the ZF6-DB approach with 1 or more additional genes would be needed to support the hypothesis that DNA binding proteins can be used broadly to regulate gene expression. Such data needs to be added to the manuscript, or the manuscript needs to be revised to focus on the specific application of this approach to the RHO gene.

2) The level of repression of the RHO gene achieved in the repression-replacement experiment described in Figure 4 is moderate. It is likely that greater than 35% suppression of a mutant RHO allele would be needed to have a therapeutic effect for patients affected by retinal degeneration due to gain-of-function mutations in RHO. While the data reported in Figure 1 suggest that repression of RHO expression in transduced photoreceptor cells is closer to 90%, it is unclear if suppressing RHO expression in 35% of photoreceptor cells would be therapeutic. Additional experiments to optimize the dose response and evaluate the potential of this approach for therapeutic use are needed to support the claim that a ZF6-DB based approach has the potential to be used clinically.

3) Along these lines, the experiment testing the activity of the ZF6-DB in the transgenic RHO-P347S mice is helpful, but does not support the use of the ZF6-DB mediated RHO repression approach in patients, since the mutant human transgene is present on a mouse background. It would be better to test the activity of the ZF6-DB in a model with a mutant mouse allele, and include the complete repression-replacement approach in these studies.

4) The ChIP experiment is helpful to show occupancy of the RHO CRE by ZF6-DB. It would be helpful to report what other sequences were detected in the ChIP experiment. That is, what else does the RHO ZF6-DB bind to? Additional ChIP data to address the question of what proteins normally occupy the RHO regulatory element would also be helpful.

5) The repression of GNAT1 expression observed following treatment with the RHO ZF6-DB is interesting. Is there a similar CRE upstream of the GNAT1 gene? Or is some other mechanism responsible to the linked regulation of expression, as suggested by the data in Figure 4? Further exploration of this issue is warranted.

6) The relative specificity of the ZF6-DB activity compared to that observed using the hybrid ZF6-DB-KRAB ED protein is impressive. Other studies have used more than 30 million sequence reads to sample gene expression by the neural retina thoroughly. It would be helpful to know why 30 million reads were used in this study, and if this provides complete sampling of retinal transcripts.

7) The discussion about the mechanism of ZFN-DB activity is interesting, but is beyond the data available in the current manuscript. The Discussion would be better focusing on interpreting the data in the manuscript.

Reviewer #3:

Botta and colleagues report on in vivo targeted silencing of rhodopsin expression by transcription factor proteins -with and without effector domain (ED)- engineered to recognize a 20 bp-cis-regulatory element of the proximal region of the rhodopsin promoter. They provide data which support the view that both engineered transcription factor proteins, with and without ED, suppresses rhodospin expression by DNA binding with similar affinities to the 20 bp-cis-regulatory element. They show that the engineered transcription factor lacking the effector domain silences rather specifically the expression of rhodopsin gene as determined by transcriptome analyses. They report that AAV-based delivery of the engineered rhodopsin-specific transcription factor protein without ED to the retina of a transgenic mouse with a human rhodopsin gene harboring a dominant negative RHO mutation prevented retinal degeneration. Finally, as a first step towards the use of this original strategy in the clinics, they nicely demonstrate that AAV-based delivery of pig-specific rhodospin silencing transcription factor protein without ED and of human Rhodopsin permitted preservation of retinal cells which deprived of pig-rhodopsin expressed the human counterpart.

This is very nicely designed and executed study with real therapeutic promises. I have no major concern regarding the scientific aspects of this sound work.

I have however a major critic regarding the writing of the manuscript which makes this beautiful piece of work sometimes very hard to follow. Here are some points to clarify:

1) Figure 1A: I would suggest to show clearly which nucleotide corresponds to +1 and which is the -84 -65 ZF6-cis sequence and to provide a legend mentioning each of the CRE that appear on the scheme.

2) Figures 1C and 1E are a little confusing as in 1C the green corresponds to the e-GFP whereas in 1E that is just below the green labels the rhodopsin.

3) Anti-HA is used both in immunochemistry and CHIP analysis but it is not clearly mentioned that the constructs which were used encode this flag.

4) CHIP-seq analysis: I would suggest to precise before giving the results a short sentence describing what was done, i.e. AAV-based delivery of constructs encoding eGFP or silencing transcription factor protein with or without ED in HEK293 cells, immunoprecipitation using the HA tag and RT-PCR amplification using primers flanking (where are they by the way?). The supporting figure is obscure. What are the MOCKs? Why is there no mention of the results using the CMV-ZF6-KRAB construct?

In these experiments AAV2.1vectors were used whereas some others used AAV8. Not all the readers are aware of their tropism differences.

5) Transcriptomic analyses. Despite the importance of this analysis I have been unable to find in the manuscript reference to what was exactly done. How were the transduced cells collected? Were the transduced regions microdissected and then the rods FACs sorted? How were the mRNA outputs from the transduced versus the untransduced regions matched?

Overall, I would suggest the authors to submit their revised manuscript to a colleague that is not involved in this work to ensure clarity.

[Editors' note: further revisions were requested prior to acceptance, as described below.]

Thank you for resubmitting your work entitled "RHODOPSIN-targeted transcriptional silencing by DNA-binding" for further consideration at eLife. Your revised article has been favorably evaluated by a Senior editor and Jeremy Nathans as the Reviewing editor. The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

It looks substantially improved, but there is one aspect of the writing that needs work: various words or phrases that imply an absolute or extreme conclusion are over-stating the data. For example, in the Abstract is the phrase "complete gene silencing". The data do not support the use of the word "complete" – indeed, quantitative biological data only rarely support the use of that word. The best one can say of any observation of this type is that the signal is below the limit of detection. I suggest substituting the word "efficient" for "complete". Similarly, in the title of the legend to Figure 1 is the phrase "abolishes Rho expression". I suggest changing this to "dramatically reduces Rho expression". Please go through the manuscript carefully to make changes of this sort. My view is that your data speaks for itself, and that the manuscript should be carefully written so as to avoid over-stating the data.